[1]谢庆华△ 张昌攀 张丰毅 庄至坤 吴昭克 徐福东.壮骨通痹丸治疗肾阳虚型膝骨关节炎的疗效观察[J].中国中医骨伤科杂志,2020,28(01):49-51.
　XIE Qinghua ZHANG Changpan ZHANG Fengyi ZHUANG Zhikun WU Zhaoke XU Fudong.Clinical Efficacy of Zhuanggu Tongbi Pill in Treating Knee Osteoarthritis of Kidney-Yang Deficiency Type[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2020,28(01):49-51.
点击复制

壮骨通痹丸治疗肾阳虚型膝骨关节炎的疗效观察()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第28卷
期数:
2020年01期
页码:
49-51
栏目:
临床论著
出版日期:
2020-01-15

文章信息/Info

Title:
Clinical Efficacy of Zhuanggu Tongbi Pill in Treating Knee Osteoarthritis of Kidney-Yang Deficiency Type
文章编号:
1005-0205(2020)01-0049-03
作者:
谢庆华1△ 张昌攀1 张丰毅1 庄至坤1 吴昭克1 徐福东1
1福建泉州市正骨医院(福建 泉州,362000)
Author(s):
XIE Qinghua1△ ZHANG Changpan1 ZHANG Fengyi1 ZHUANG Zhikun1 WU Zhaoke1 XU Fudong1
1Quanzhou Orthopedic-Traumatological Hospital,Quanzhou 362000,Fujian China.
关键词:
膝骨关节炎;  壮骨通痹丸;  西乐葆;  肾阳虚
Keywords:
knee osteoarthritis;  Zhuanggu Tongbi pill;  celebrex;  Kidney-Yang deficiency type
分类号:
R684.3
文献标志码:
A
摘要:
目的:观察壮骨通痹丸口服治疗肾阳虚型膝骨关节炎(KOA)的临床疗效。方法:将90例确诊膝骨关节炎,且具有肾阳虚主要证侯表现的病人随机分为2组,每组45例。治疗组45例予口服壮骨通痹丸,每次6 g,2次/d; 对照组45例予口服西乐葆,每次200 mg,1次/d; 两组治疗时间均为6周。分别观察比较两组治疗前及治疗后第1周、第3周、第6周、3个月、6个月的VAS评分、WOMAC评分,评价壮骨通痹丸的临床疗效。结果:服药后,两组膝关节VAS评分及WOMAC评分与治疗前比较均有改善,差异有统计学意义(P<0.05),其中在治疗后第1周时,对照组优于治疗组,差异有统计学意义(P<0.05); 随着用药时间延长,第3周时两组差异无统计学意义(P>0.05),第6周、3个月、6个月时,治疗组优于对照组,差异有统计学意义(P<0.05)。观察期间,治疗组均未发现明显不良反应; 对照组出现2例胃肠道不适,1例心前区闷痛。结论:壮骨通痹丸治疗肾阳虚型KOA疗效确切,且疗效维持时间长,药物安全性好。
Abstract:
Objective:To observe clinical efficacy of Zhuanggu Tongbi pill in treating knee osteoarthritis(KOA)of kidney-yang deficiency type.Methods:Ninety patients with KOA of kidney-yang deficiency type were randomly divided into 2 groups with 45 patients in each group.The treatment group(45 patients)were orally given Zhuanggu Tongbi pill twice per day with 6 g in each time.The control group(45 patients)were orally given Celecoxib capsules daily with 200 mg.Treatment time in both groups was 6 weeks.VAS scores and WOMAC scores of the two groups were observed and compared before and after treatment at the 1st,3rd and 6th week,3 and 6 months respectively,which evaluated the clinical effect of Zhuanggu Tongbi pill.Results:VAS scores and WOMAC scores of knee joints in both groups were improved after taking the medicine compared with those before treatment(P<0.05),The control group was better than the treatment group at the first week after treatment(P<0.05).With the extension of medication duration,there were no significant differences between the two groups at the 3rd week(P>0.05),and the treatment group was better than the control group at the 6 weeks,3 and 6 months(P<0.05).During the observation period,no obvious adverse reactions were found in the treatment group.In the control group,there were 2 cases exhibited gastrointestinal discomfort and 1 case with antecardial pain.Conclusion:Zhuanggu Tongbi pill can effectively treat KOA of Kidney-Yang deficiency type,and this effect can be maintained for a long time.

参考文献/References:

[1] 郝胜坤,纪斌,石继祥,等.补肾活血中药治疗膝骨关节炎的作用机制[J].中医正骨,2017,29(4):31-33.
[2] HERRERO-BEAUMONT G,ROMAN-BLAS J A,BRU-YERE O,et al.Clinical settings in knee osteoarthritis:pathophysiology guides treatment[J].Maturitas,2017,96(2):54-57.
[3] 陈卫衡,刘献祥,童培建,等.膝骨关节炎中医诊疗专家共识(2015年版)[J].中医正骨,2015,27(7):4-5.
[4] 田惠萍,刘莹,王海洋,等.膝骨关节炎的中医药治疗临床研究进展[J].风湿病与关节炎,2018,7(1):67-71.
[5] 中华医学会骨科学分会.骨关节炎诊治指南(2007年版)[J].中华骨科杂志,2007,27(10):793-796.
[6] BELLAMY N,KIRWAN J,BOERS M,et al.Reconnendations for acore set outcome measure for future phase Ⅲ clinical trialsin knee,hip and hand OA [J].J Rheumatol,1997,24(4):799-802.
[7] DECOCTION X,WANG S,ZHAN S,et al.The prevalence of symptomaticknee osteoarthritis in China:results from the china health and retirement longitudinal study[J].Arthritis Rheumatol,2016,68(3):648-653.
[8] PULJAK L,MARIN A,VRDOLJAK D,et al.Celecoxib for osteoarthritis[J].Cochrane Database Syst Rev,2017,22(5):198-205.
[9] 国家中医药管理局.中医病症诊断疗效标准[S].南京:南京大学出版社,1994:30-31.
[10] 李具宝,张磊,屈尚可,等.膝骨关节炎近10年文献中内服方药功效和中医证型分析[J].中国中医骨伤科杂志,2014,22(3):20-21.
[11] FELSON D T.Intra-articular corticosteroids and knee osteoarthritis:interpreting different meta-analyses[J].JAMA,2016,316(24):2607-2608.

备注/Memo

备注/Memo:
△通信作者 E-mail:389922526@qq.com(收稿日期:2019-07-02)
更新日期/Last Update: 2020-01-15